Table 1.

Summary of the references and GRADE scores (confidence in cumulative evidence)

Drug	Number and type of publications	References	GRADE	CEBM
Abatacept	1 cohort, 2 register data (2 abstracts), 2 case reports/series (1 abstracts)	[9, 20–23]	++	3–4
Adalimumab	19 cohorts (9 abstract), 14 register data (6 abstract), 6 case controls (1 abstract), 11 case reports/series (3 abstract)	[1, 20–69]	+++	3
Anakinra	4 cohorts (1 abstract), 2 case reports/series	[20, 57, 70–73]	+	4
Canakinumab	1 cohort, 1 case report (1 abstract)	[72, 74]	+	4
Certolizumab pegol	14 cohorts (6 abstract), 10 register data (1 abstract), 4 case controls (1 abstract), 4 case reports/series (3 abstract)	[1, 20, 22, 23, 31, 33, 37, 39, 40, 42, 44, 48, 54, 55, 57, 58, 63, 64, 66, 68, 75–88]	++	3–4
Etanercept	12 cohorts (5 abstract), 6 register data (2 abstract), 2 case controls (1 abstract), 6 case reports/series (2 abstract)	[1, 20–23, 27, 33, 35, 40, 41, 44, 45, 47, 53–57, 60, 63, 66, 68, 87, 89–91]	+++	3
Golimumab	9 cohorts (2 abstract), 3 register data (1 abstract), 2 case controls (1 abstract), 2 case reports/series (1 abstract)	[20, 22, 23, 33, 35, 40, 44, 48, 53–55, 58, 64, 66, 68, 80]	+	4
Infliximab	23 cohorts (11 abstract), 13 register data (2 abstract), 3 case controls, 20 case reports/series (10 abstract)	[1, 20–25, 28, 31, 34–38, 40, 42–44, 46–48, 51, 53, 55, 57, 58, 60–62, 64–68, 76, 77, 79, 80, 92–112]	++	3–4
Rituximab	5 cohorts (2 abstract), 3 register data (2 abstract), 1 case reports/series (1 abstract)	[20, 22, 44, 45, 56, 57, 63, 66, 113]	+	4
Tocilizumab	1 cohort, 1 register data (1 abstract), 8 case reports/series (3 abstract)	[22, 23, 41, 45, 114–119]	++	3–4
Ustekinumab	4 cohorts, 3 register data (2 abstract), 15 case reports/series (3 abstract)	[27, 37, 44, 53, 59, 60, 64, 66, 67, 77, 80, 120–130]	+	4
Vedolizumab	2 cohorts (1 abstract), 1 register data, 2 case controls (1 abstract), 2 case reports/series (1 abstract)	[64, 77, 131–135]	+	4